Vanguard Group
MTCR

Vanguard Group’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Vanguard Group’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-254,492
Closed -$114K – 4630
2022
Q4 		$114K Hold
254,492
– – ﹤0.01% 4377
2022
Q3 		$123K Sell
254,492
-193,934
-43% -$95.4K ﹤0.01% 4474
2022
Q2 		$225K Buy
448,426
+15,122
+3% +$7.32K ﹤0.01% 4457
2022
Q1 		$264K Buy
433,304
+922
+0.2% +$483 ﹤0.01% 4497
2021
Q4 		$291K Buy
432,382
+20,000
+5% +$35.7K ﹤0.01% 4517
2021
Q3 		$1.42M Buy
412,382
+4,302
+1% +$13.4K ﹤0.01% 4161
2021
Q2 		$1.55M Buy
408,080
+160,809
+65% +$665K ﹤0.01% 4040
2021
Q1 		$1.53M Buy
247,271
+146,872
+146% +$1.3M ﹤0.01% 3920
2020
Q4 		$789K Buy
100,399
+20,399
+25% +$187K ﹤0.01% 3882
2020
Q3 		$817K Buy
+80,000
New +$819K ﹤0.01% 3705

Other funds holding MTCR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Vanguard Group's MTCR Position: Q1 2023 in Review

Vanguard Group sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 254,492 shares — an estimated $114K sold.

Vanguard Group first reported a position in MTCR in Q3 2020 and held it in 10 quarters. The position peaked at $1.55M in Q2 2021. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Vanguard Group reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 254,492 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $114K.
  • Vanguard Group first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 10 quarters.
  • Vanguard Group's Metacrine, Inc. Common Stock position peaked at $1.55M in Q2 2021.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.